nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—MTOR—liver cancer	0.554	1	CbGaD
Sirolimus—CYP3A7—Sorafenib—liver cancer	0.0385	0.25	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.0385	0.25	CbGbCtD
Sirolimus—CYP3A5—Sorafenib—liver cancer	0.0289	0.187	CbGbCtD
Sirolimus—ABCB1—Sorafenib—liver cancer	0.0188	0.122	CbGbCtD
Sirolimus—ABCB1—Doxorubicin—liver cancer	0.0114	0.074	CbGbCtD
Sirolimus—CYP3A4—Sorafenib—liver cancer	0.0113	0.0731	CbGbCtD
Sirolimus—CYP3A4—Doxorubicin—liver cancer	0.00684	0.0443	CbGbCtD
Sirolimus—Pimecrolimus—MTOR—liver cancer	0.00192	0.296	CrCbGaD
Sirolimus—Everolimus—MTOR—liver cancer	0.00192	0.296	CrCbGaD
Sirolimus—Temsirolimus—MTOR—liver cancer	0.0013	0.2	CrCbGaD
Sirolimus—Tacrolimus—MTOR—liver cancer	0.00114	0.176	CrCbGaD
Sirolimus—Tacrolimus—ALB—liver cancer	0.000206	0.0317	CrCbGaD
Sirolimus—Abdominal pain—Sorafenib—liver cancer	0.000184	0.00129	CcSEcCtD
Sirolimus—Body temperature increased—Sorafenib—liver cancer	0.000184	0.00129	CcSEcCtD
Sirolimus—Renal impairment—Epirubicin—liver cancer	0.000184	0.00129	CcSEcCtD
Sirolimus—Anaphylactoid reaction—Epirubicin—liver cancer	0.000181	0.00127	CcSEcCtD
Sirolimus—Hepatic failure—Doxorubicin—liver cancer	0.00018	0.00126	CcSEcCtD
Sirolimus—Hypoglycaemia—Epirubicin—liver cancer	0.000179	0.00126	CcSEcCtD
Sirolimus—Cardiac failure congestive—Doxorubicin—liver cancer	0.000178	0.00125	CcSEcCtD
Sirolimus—Hyponatraemia—Epirubicin—liver cancer	0.000176	0.00123	CcSEcCtD
Sirolimus—Osteoarthritis—Epirubicin—liver cancer	0.000175	0.00123	CcSEcCtD
Sirolimus—Increased appetite—Doxorubicin—liver cancer	0.000172	0.00121	CcSEcCtD
Sirolimus—Affect lability—Epirubicin—liver cancer	0.000172	0.00121	CcSEcCtD
Sirolimus—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000172	0.0012	CcSEcCtD
Sirolimus—Hypersensitivity—Sorafenib—liver cancer	0.000171	0.0012	CcSEcCtD
Sirolimus—Renal impairment—Doxorubicin—liver cancer	0.00017	0.00119	CcSEcCtD
Sirolimus—Face oedema—Epirubicin—liver cancer	0.000169	0.00119	CcSEcCtD
Sirolimus—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000167	0.00117	CcSEcCtD
Sirolimus—Asthenia—Sorafenib—liver cancer	0.000167	0.00117	CcSEcCtD
Sirolimus—Hypoglycaemia—Doxorubicin—liver cancer	0.000166	0.00116	CcSEcCtD
Sirolimus—Mood swings—Epirubicin—liver cancer	0.000166	0.00116	CcSEcCtD
Sirolimus—Pruritus—Sorafenib—liver cancer	0.000165	0.00116	CcSEcCtD
Sirolimus—Blood creatinine increased—Epirubicin—liver cancer	0.000164	0.00115	CcSEcCtD
Sirolimus—Dehydration—Epirubicin—liver cancer	0.000163	0.00114	CcSEcCtD
Sirolimus—Hyponatraemia—Doxorubicin—liver cancer	0.000163	0.00114	CcSEcCtD
Sirolimus—Osteoarthritis—Doxorubicin—liver cancer	0.000162	0.00114	CcSEcCtD
Sirolimus—Liver function test abnormal—Epirubicin—liver cancer	0.000162	0.00113	CcSEcCtD
Sirolimus—Orthostatic hypotension—Epirubicin—liver cancer	0.00016	0.00112	CcSEcCtD
Sirolimus—Affect lability—Doxorubicin—liver cancer	0.000159	0.00112	CcSEcCtD
Sirolimus—Hypokalaemia—Epirubicin—liver cancer	0.000159	0.00112	CcSEcCtD
Sirolimus—Diarrhoea—Sorafenib—liver cancer	0.000159	0.00112	CcSEcCtD
Sirolimus—Breast disorder—Epirubicin—liver cancer	0.000158	0.00111	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000158	0.00111	CcSEcCtD
Sirolimus—Face oedema—Doxorubicin—liver cancer	0.000156	0.0011	CcSEcCtD
Sirolimus—Gastritis—Epirubicin—liver cancer	0.000155	0.00109	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000154	0.00108	CcSEcCtD
Sirolimus—Dizziness—Sorafenib—liver cancer	0.000154	0.00108	CcSEcCtD
Sirolimus—Mood swings—Doxorubicin—liver cancer	0.000153	0.00108	CcSEcCtD
Sirolimus—Abdominal distension—Epirubicin—liver cancer	0.000152	0.00107	CcSEcCtD
Sirolimus—Blood creatinine increased—Doxorubicin—liver cancer	0.000152	0.00106	CcSEcCtD
Sirolimus—Dysphagia—Epirubicin—liver cancer	0.000151	0.00106	CcSEcCtD
Sirolimus—Asthma—Epirubicin—liver cancer	0.000151	0.00106	CcSEcCtD
Sirolimus—Influenza—Epirubicin—liver cancer	0.000151	0.00106	CcSEcCtD
Sirolimus—Dehydration—Doxorubicin—liver cancer	0.000151	0.00106	CcSEcCtD
Sirolimus—Liver function test abnormal—Doxorubicin—liver cancer	0.000149	0.00105	CcSEcCtD
Sirolimus—Pancreatitis—Epirubicin—liver cancer	0.000148	0.00104	CcSEcCtD
Sirolimus—Vomiting—Sorafenib—liver cancer	0.000148	0.00104	CcSEcCtD
Sirolimus—Orthostatic hypotension—Doxorubicin—liver cancer	0.000148	0.00104	CcSEcCtD
Sirolimus—Hypokalaemia—Doxorubicin—liver cancer	0.000147	0.00103	CcSEcCtD
Sirolimus—Rash—Sorafenib—liver cancer	0.000147	0.00103	CcSEcCtD
Sirolimus—Dermatitis—Sorafenib—liver cancer	0.000147	0.00103	CcSEcCtD
Sirolimus—Breast disorder—Doxorubicin—liver cancer	0.000146	0.00103	CcSEcCtD
Sirolimus—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000146	0.00102	CcSEcCtD
Sirolimus—Headache—Sorafenib—liver cancer	0.000146	0.00102	CcSEcCtD
Sirolimus—Bronchitis—Epirubicin—liver cancer	0.000145	0.00102	CcSEcCtD
Sirolimus—Pancytopenia—Epirubicin—liver cancer	0.000144	0.00101	CcSEcCtD
Sirolimus—Gastritis—Doxorubicin—liver cancer	0.000143	0.00101	CcSEcCtD
Sirolimus—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000143	0.001	CcSEcCtD
Sirolimus—Neutropenia—Epirubicin—liver cancer	0.000141	0.000993	CcSEcCtD
Sirolimus—Dysuria—Epirubicin—liver cancer	0.000141	0.000993	CcSEcCtD
Sirolimus—Abdominal distension—Doxorubicin—liver cancer	0.000141	0.000989	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Epirubicin—liver cancer	0.000141	0.000987	CcSEcCtD
Sirolimus—Asthma—Doxorubicin—liver cancer	0.00014	0.000982	CcSEcCtD
Sirolimus—Influenza—Doxorubicin—liver cancer	0.00014	0.000982	CcSEcCtD
Sirolimus—Dysphagia—Doxorubicin—liver cancer	0.00014	0.000982	CcSEcCtD
Sirolimus—Pollakiuria—Epirubicin—liver cancer	0.00014	0.000981	CcSEcCtD
Sirolimus—Nausea—Sorafenib—liver cancer	0.000138	0.00097	CcSEcCtD
Sirolimus—Weight increased—Epirubicin—liver cancer	0.000138	0.000966	CcSEcCtD
Sirolimus—Pancreatitis—Doxorubicin—liver cancer	0.000137	0.000963	CcSEcCtD
Sirolimus—Weight decreased—Epirubicin—liver cancer	0.000137	0.00096	CcSEcCtD
Sirolimus—Hyperglycaemia—Epirubicin—liver cancer	0.000136	0.000958	CcSEcCtD
Sirolimus—Pneumonia—Epirubicin—liver cancer	0.000136	0.000952	CcSEcCtD
Sirolimus—Infestation—Epirubicin—liver cancer	0.000135	0.000946	CcSEcCtD
Sirolimus—Infestation NOS—Epirubicin—liver cancer	0.000135	0.000946	CcSEcCtD
Sirolimus—Bronchitis—Doxorubicin—liver cancer	0.000135	0.000945	CcSEcCtD
Sirolimus—Pancytopenia—Doxorubicin—liver cancer	0.000133	0.000933	CcSEcCtD
Sirolimus—Neuropathy peripheral—Epirubicin—liver cancer	0.000132	0.000928	CcSEcCtD
Sirolimus—Stomatitis—Epirubicin—liver cancer	0.000131	0.000923	CcSEcCtD
Sirolimus—Urinary tract infection—Epirubicin—liver cancer	0.000131	0.00092	CcSEcCtD
Sirolimus—Conjunctivitis—Epirubicin—liver cancer	0.000131	0.00092	CcSEcCtD
Sirolimus—Dysuria—Doxorubicin—liver cancer	0.000131	0.000918	CcSEcCtD
Sirolimus—Neutropenia—Doxorubicin—liver cancer	0.000131	0.000918	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00013	0.000913	CcSEcCtD
Sirolimus—Sweating—Epirubicin—liver cancer	0.000129	0.000907	CcSEcCtD
Sirolimus—Pollakiuria—Doxorubicin—liver cancer	0.000129	0.000907	CcSEcCtD
Sirolimus—Haematuria—Epirubicin—liver cancer	0.000129	0.000902	CcSEcCtD
Sirolimus—Hepatobiliary disease—Epirubicin—liver cancer	0.000127	0.000895	CcSEcCtD
Sirolimus—Weight increased—Doxorubicin—liver cancer	0.000127	0.000894	CcSEcCtD
Sirolimus—Epistaxis—Epirubicin—liver cancer	0.000127	0.000893	CcSEcCtD
Sirolimus—Weight decreased—Doxorubicin—liver cancer	0.000127	0.000889	CcSEcCtD
Sirolimus—Sinusitis—Epirubicin—liver cancer	0.000126	0.000888	CcSEcCtD
Sirolimus—Hyperglycaemia—Doxorubicin—liver cancer	0.000126	0.000886	CcSEcCtD
Sirolimus—Pneumonia—Doxorubicin—liver cancer	0.000125	0.000881	CcSEcCtD
Sirolimus—Infestation NOS—Doxorubicin—liver cancer	0.000125	0.000876	CcSEcCtD
Sirolimus—Infestation—Doxorubicin—liver cancer	0.000125	0.000876	CcSEcCtD
Sirolimus—Neuropathy peripheral—Doxorubicin—liver cancer	0.000122	0.000858	CcSEcCtD
Sirolimus—Haemoglobin—Epirubicin—liver cancer	0.000122	0.000854	CcSEcCtD
Sirolimus—Stomatitis—Doxorubicin—liver cancer	0.000122	0.000854	CcSEcCtD
Sirolimus—Rhinitis—Epirubicin—liver cancer	0.000121	0.000852	CcSEcCtD
Sirolimus—Urinary tract infection—Doxorubicin—liver cancer	0.000121	0.000851	CcSEcCtD
Sirolimus—Conjunctivitis—Doxorubicin—liver cancer	0.000121	0.000851	CcSEcCtD
Sirolimus—Haemorrhage—Epirubicin—liver cancer	0.000121	0.00085	CcSEcCtD
Sirolimus—Hypoaesthesia—Epirubicin—liver cancer	0.00012	0.000845	CcSEcCtD
Sirolimus—Pharyngitis—Epirubicin—liver cancer	0.00012	0.000843	CcSEcCtD
Sirolimus—Sweating—Doxorubicin—liver cancer	0.00012	0.00084	CcSEcCtD
Sirolimus—Urinary tract disorder—Epirubicin—liver cancer	0.00012	0.000839	CcSEcCtD
Sirolimus—Oedema peripheral—Epirubicin—liver cancer	0.000119	0.000837	CcSEcCtD
Sirolimus—Haematuria—Doxorubicin—liver cancer	0.000119	0.000835	CcSEcCtD
Sirolimus—Connective tissue disorder—Epirubicin—liver cancer	0.000119	0.000835	CcSEcCtD
Sirolimus—Urethral disorder—Epirubicin—liver cancer	0.000119	0.000833	CcSEcCtD
Sirolimus—Hepatobiliary disease—Doxorubicin—liver cancer	0.000118	0.000828	CcSEcCtD
Sirolimus—Epistaxis—Doxorubicin—liver cancer	0.000118	0.000826	CcSEcCtD
Sirolimus—Sinusitis—Doxorubicin—liver cancer	0.000117	0.000822	CcSEcCtD
Sirolimus—Visual impairment—Epirubicin—liver cancer	0.000117	0.000819	CcSEcCtD
Sirolimus—Tinnitus—Epirubicin—liver cancer	0.000113	0.000792	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—liver cancer	0.000113	0.00079	CcSEcCtD
Sirolimus—Cardiac disorder—Epirubicin—liver cancer	0.000112	0.000789	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—liver cancer	0.000112	0.000788	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—liver cancer	0.000112	0.000786	CcSEcCtD
Sirolimus—Hypoaesthesia—Doxorubicin—liver cancer	0.000111	0.000782	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—liver cancer	0.000111	0.00078	CcSEcCtD
Sirolimus—Urinary tract disorder—Doxorubicin—liver cancer	0.000111	0.000776	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—liver cancer	0.00011	0.000774	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—liver cancer	0.00011	0.000773	CcSEcCtD
Sirolimus—Angiopathy—Epirubicin—liver cancer	0.00011	0.000771	CcSEcCtD
Sirolimus—Urethral disorder—Doxorubicin—liver cancer	0.00011	0.000771	CcSEcCtD
Sirolimus—Immune system disorder—Epirubicin—liver cancer	0.000109	0.000767	CcSEcCtD
Sirolimus—Mediastinal disorder—Epirubicin—liver cancer	0.000109	0.000766	CcSEcCtD
Sirolimus—Chills—Epirubicin—liver cancer	0.000109	0.000762	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—liver cancer	0.000108	0.000758	CcSEcCtD
Sirolimus—Malnutrition—Epirubicin—liver cancer	0.000105	0.00074	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—liver cancer	0.000104	0.000733	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—liver cancer	0.000104	0.00073	CcSEcCtD
Sirolimus—Flatulence—Epirubicin—liver cancer	0.000104	0.000729	CcSEcCtD
Sirolimus—Tension—Epirubicin—liver cancer	0.000103	0.000726	CcSEcCtD
Sirolimus—Nervousness—Epirubicin—liver cancer	0.000102	0.000718	CcSEcCtD
Sirolimus—Back pain—Epirubicin—liver cancer	0.000102	0.000715	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—liver cancer	0.000102	0.000713	CcSEcCtD
Sirolimus—Muscle spasms—Epirubicin—liver cancer	0.000101	0.000711	CcSEcCtD
Sirolimus—Immune system disorder—Doxorubicin—liver cancer	0.000101	0.00071	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—liver cancer	0.000101	0.000709	CcSEcCtD
Sirolimus—Chills—Doxorubicin—liver cancer	0.0001	0.000705	CcSEcCtD
Sirolimus—Ill-defined disorder—Epirubicin—liver cancer	9.77e-05	0.000686	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—liver cancer	9.75e-05	0.000684	CcSEcCtD
Sirolimus—Anaemia—Epirubicin—liver cancer	9.74e-05	0.000684	CcSEcCtD
Sirolimus—Agitation—Epirubicin—liver cancer	9.68e-05	0.00068	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—liver cancer	9.61e-05	0.000674	CcSEcCtD
Sirolimus—Tension—Doxorubicin—liver cancer	9.57e-05	0.000672	CcSEcCtD
Sirolimus—Malaise—Epirubicin—liver cancer	9.5e-05	0.000667	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—liver cancer	9.47e-05	0.000665	CcSEcCtD
Sirolimus—Syncope—Epirubicin—liver cancer	9.45e-05	0.000663	CcSEcCtD
Sirolimus—Leukopenia—Epirubicin—liver cancer	9.43e-05	0.000662	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—liver cancer	9.43e-05	0.000662	CcSEcCtD
Sirolimus—Muscle spasms—Doxorubicin—liver cancer	9.37e-05	0.000658	CcSEcCtD
Sirolimus—Palpitations—Epirubicin—liver cancer	9.31e-05	0.000654	CcSEcCtD
Sirolimus—Loss of consciousness—Epirubicin—liver cancer	9.26e-05	0.00065	CcSEcCtD
Sirolimus—Cough—Epirubicin—liver cancer	9.19e-05	0.000645	CcSEcCtD
Sirolimus—Hypertension—Epirubicin—liver cancer	9.1e-05	0.000639	CcSEcCtD
Sirolimus—Ill-defined disorder—Doxorubicin—liver cancer	9.04e-05	0.000635	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—liver cancer	9.01e-05	0.000633	CcSEcCtD
Sirolimus—Chest pain—Epirubicin—liver cancer	8.97e-05	0.00063	CcSEcCtD
Sirolimus—Myalgia—Epirubicin—liver cancer	8.97e-05	0.00063	CcSEcCtD
Sirolimus—Arthralgia—Epirubicin—liver cancer	8.97e-05	0.00063	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—liver cancer	8.96e-05	0.000629	CcSEcCtD
Sirolimus—Anxiety—Epirubicin—liver cancer	8.94e-05	0.000628	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	8.91e-05	0.000625	CcSEcCtD
Sirolimus—Discomfort—Epirubicin—liver cancer	8.86e-05	0.000622	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—liver cancer	8.79e-05	0.000617	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—liver cancer	8.74e-05	0.000614	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—liver cancer	8.73e-05	0.000613	CcSEcCtD
Sirolimus—Confusional state—Epirubicin—liver cancer	8.67e-05	0.000609	CcSEcCtD
Sirolimus—Palpitations—Doxorubicin—liver cancer	8.61e-05	0.000605	CcSEcCtD
Sirolimus—Anaphylactic shock—Epirubicin—liver cancer	8.6e-05	0.000604	CcSEcCtD
Sirolimus—Oedema—Epirubicin—liver cancer	8.6e-05	0.000604	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—liver cancer	8.57e-05	0.000601	CcSEcCtD
Sirolimus—Infection—Epirubicin—liver cancer	8.54e-05	0.0006	CcSEcCtD
Sirolimus—Cough—Doxorubicin—liver cancer	8.51e-05	0.000597	CcSEcCtD
Sirolimus—Shock—Epirubicin—liver cancer	8.46e-05	0.000594	CcSEcCtD
Sirolimus—Nervous system disorder—Epirubicin—liver cancer	8.43e-05	0.000592	CcSEcCtD
Sirolimus—Thrombocytopenia—Epirubicin—liver cancer	8.42e-05	0.000591	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—liver cancer	8.42e-05	0.000591	CcSEcCtD
Sirolimus—Tachycardia—Epirubicin—liver cancer	8.39e-05	0.000589	CcSEcCtD
Sirolimus—Skin disorder—Epirubicin—liver cancer	8.35e-05	0.000586	CcSEcCtD
Sirolimus—Hyperhidrosis—Epirubicin—liver cancer	8.31e-05	0.000584	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—liver cancer	8.3e-05	0.000583	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—liver cancer	8.3e-05	0.000583	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—liver cancer	8.3e-05	0.000583	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—liver cancer	8.27e-05	0.000581	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	8.24e-05	0.000579	CcSEcCtD
Sirolimus—Discomfort—Doxorubicin—liver cancer	8.2e-05	0.000576	CcSEcCtD
Sirolimus—Anorexia—Epirubicin—liver cancer	8.2e-05	0.000575	CcSEcCtD
Sirolimus—Hypotension—Epirubicin—liver cancer	8.03e-05	0.000564	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—liver cancer	8.02e-05	0.000563	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—liver cancer	7.96e-05	0.000559	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—liver cancer	7.96e-05	0.000559	CcSEcCtD
Sirolimus—Infection—Doxorubicin—liver cancer	7.9e-05	0.000555	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Epirubicin—liver cancer	7.83e-05	0.00055	CcSEcCtD
Sirolimus—Shock—Doxorubicin—liver cancer	7.83e-05	0.00055	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—liver cancer	7.8e-05	0.000548	CcSEcCtD
Sirolimus—Thrombocytopenia—Doxorubicin—liver cancer	7.79e-05	0.000547	CcSEcCtD
Sirolimus—Insomnia—Epirubicin—liver cancer	7.78e-05	0.000546	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—liver cancer	7.76e-05	0.000545	CcSEcCtD
Sirolimus—Skin disorder—Doxorubicin—liver cancer	7.73e-05	0.000543	CcSEcCtD
Sirolimus—Paraesthesia—Epirubicin—liver cancer	7.72e-05	0.000542	CcSEcCtD
Sirolimus—Hyperhidrosis—Doxorubicin—liver cancer	7.69e-05	0.00054	CcSEcCtD
Sirolimus—Dyspnoea—Epirubicin—liver cancer	7.67e-05	0.000538	CcSEcCtD
Sirolimus—Somnolence—Epirubicin—liver cancer	7.64e-05	0.000537	CcSEcCtD
Sirolimus—Anorexia—Doxorubicin—liver cancer	7.58e-05	0.000532	CcSEcCtD
Sirolimus—Dyspepsia—Epirubicin—liver cancer	7.57e-05	0.000531	CcSEcCtD
Sirolimus—Decreased appetite—Epirubicin—liver cancer	7.47e-05	0.000525	CcSEcCtD
Sirolimus—Hypotension—Doxorubicin—liver cancer	7.43e-05	0.000522	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Epirubicin—liver cancer	7.42e-05	0.000521	CcSEcCtD
Sirolimus—Pain—Epirubicin—liver cancer	7.35e-05	0.000516	CcSEcCtD
Sirolimus—Constipation—Epirubicin—liver cancer	7.35e-05	0.000516	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—liver cancer	7.25e-05	0.000509	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—liver cancer	7.2e-05	0.000505	CcSEcCtD
Sirolimus—Paraesthesia—Doxorubicin—liver cancer	7.14e-05	0.000502	CcSEcCtD
Sirolimus—Dyspnoea—Doxorubicin—liver cancer	7.09e-05	0.000498	CcSEcCtD
Sirolimus—Feeling abnormal—Epirubicin—liver cancer	7.09e-05	0.000497	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—liver cancer	7.07e-05	0.000497	CcSEcCtD
Sirolimus—Gastrointestinal pain—Epirubicin—liver cancer	7.03e-05	0.000494	CcSEcCtD
Sirolimus—Dyspepsia—Doxorubicin—liver cancer	7e-05	0.000492	CcSEcCtD
Sirolimus—Decreased appetite—Doxorubicin—liver cancer	6.92e-05	0.000486	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Doxorubicin—liver cancer	6.87e-05	0.000482	CcSEcCtD
Sirolimus—Pain—Doxorubicin—liver cancer	6.8e-05	0.000478	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—liver cancer	6.8e-05	0.000478	CcSEcCtD
Sirolimus—Abdominal pain—Epirubicin—liver cancer	6.8e-05	0.000477	CcSEcCtD
Sirolimus—Body temperature increased—Epirubicin—liver cancer	6.8e-05	0.000477	CcSEcCtD
Sirolimus—Feeling abnormal—Doxorubicin—liver cancer	6.56e-05	0.00046	CcSEcCtD
Sirolimus—Gastrointestinal pain—Doxorubicin—liver cancer	6.51e-05	0.000457	CcSEcCtD
Sirolimus—Hypersensitivity—Epirubicin—liver cancer	6.33e-05	0.000445	CcSEcCtD
Sirolimus—Body temperature increased—Doxorubicin—liver cancer	6.29e-05	0.000442	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—liver cancer	6.29e-05	0.000442	CcSEcCtD
Sirolimus—Asthenia—Epirubicin—liver cancer	6.17e-05	0.000433	CcSEcCtD
Sirolimus—Pruritus—Epirubicin—liver cancer	6.08e-05	0.000427	CcSEcCtD
Sirolimus—Diarrhoea—Epirubicin—liver cancer	5.88e-05	0.000413	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—liver cancer	5.86e-05	0.000412	CcSEcCtD
Sirolimus—Asthenia—Doxorubicin—liver cancer	5.71e-05	0.000401	CcSEcCtD
Sirolimus—Dizziness—Epirubicin—liver cancer	5.69e-05	0.000399	CcSEcCtD
Sirolimus—Pruritus—Doxorubicin—liver cancer	5.63e-05	0.000395	CcSEcCtD
Sirolimus—Vomiting—Epirubicin—liver cancer	5.47e-05	0.000384	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—liver cancer	5.44e-05	0.000382	CcSEcCtD
Sirolimus—Rash—Epirubicin—liver cancer	5.42e-05	0.000381	CcSEcCtD
Sirolimus—Dermatitis—Epirubicin—liver cancer	5.42e-05	0.00038	CcSEcCtD
Sirolimus—Headache—Epirubicin—liver cancer	5.39e-05	0.000378	CcSEcCtD
Sirolimus—Dizziness—Doxorubicin—liver cancer	5.26e-05	0.000369	CcSEcCtD
Sirolimus—Nausea—Epirubicin—liver cancer	5.11e-05	0.000359	CcSEcCtD
Sirolimus—Vomiting—Doxorubicin—liver cancer	5.06e-05	0.000355	CcSEcCtD
Sirolimus—Rash—Doxorubicin—liver cancer	5.02e-05	0.000352	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—liver cancer	5.01e-05	0.000352	CcSEcCtD
Sirolimus—Headache—Doxorubicin—liver cancer	4.98e-05	0.00035	CcSEcCtD
Sirolimus—Nausea—Doxorubicin—liver cancer	4.73e-05	0.000332	CcSEcCtD
Sirolimus—FGF2—Immune System—MAPK8—liver cancer	8.19e-06	5.74e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—APC—liver cancer	8.18e-06	5.73e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CG—liver cancer	8.18e-06	5.73e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALDOB—liver cancer	8.17e-06	5.72e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—BRAF—liver cancer	8.14e-06	5.71e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—liver cancer	8.09e-06	5.67e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CSF2—liver cancer	8.08e-06	5.66e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TGFB1—liver cancer	8.07e-06	5.66e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PSMA4—liver cancer	8.04e-06	5.63e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PSMD10—liver cancer	8.04e-06	5.63e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CYP1A1—liver cancer	7.97e-06	5.58e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—H2AFX—liver cancer	7.96e-06	5.58e-05	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—AKT1—liver cancer	7.96e-06	5.57e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—CTNNB1—liver cancer	7.93e-06	5.56e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—liver cancer	7.87e-06	5.51e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	7.85e-06	5.5e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—liver cancer	7.83e-06	5.49e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GOT2—liver cancer	7.82e-06	5.48e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CRABP1—liver cancer	7.79e-06	5.46e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	7.79e-06	5.46e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN1B—liver cancer	7.76e-06	5.43e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—CDKN1A—liver cancer	7.75e-06	5.43e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GSTM1—liver cancer	7.71e-06	5.4e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—BRAF—liver cancer	7.69e-06	5.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CD—liver cancer	7.62e-06	5.34e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CASP3—liver cancer	7.6e-06	5.33e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL2—liver cancer	7.59e-06	5.32e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	7.59e-06	5.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—SERPINE1—liver cancer	7.53e-06	5.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PIK3CA—liver cancer	7.53e-06	5.27e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—STAT3—liver cancer	7.49e-06	5.25e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—liver cancer	7.48e-06	5.24e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—MTHFR—liver cancer	7.43e-06	5.2e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—liver cancer	7.4e-06	5.18e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—JUN—liver cancer	7.39e-06	5.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—RAF1—liver cancer	7.37e-06	5.16e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP2E1—liver cancer	7.36e-06	5.15e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CTNNB1—liver cancer	7.33e-06	5.13e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CYP1A1—liver cancer	7.31e-06	5.12e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARA—liver cancer	7.29e-06	5.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PIK3CA—liver cancer	7.23e-06	5.06e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TERT—liver cancer	7.2e-06	5.04e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PIK3CA—liver cancer	7.2e-06	5.04e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CB—liver cancer	7.19e-06	5.04e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CD—liver cancer	7.19e-06	5.04e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—liver cancer	7.19e-06	5.03e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN1A—liver cancer	7.16e-06	5.02e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SERPINE1—liver cancer	7.11e-06	4.98e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK8—liver cancer	6.99e-06	4.9e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—liver cancer	6.96e-06	4.88e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—STAT3—liver cancer	6.91e-06	4.84e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYCS—liver cancer	6.88e-06	4.82e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PIK3CA—liver cancer	6.87e-06	4.81e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—MTHFR—liver cancer	6.82e-06	4.78e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HPGDS—liver cancer	6.81e-06	4.77e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—RAF1—liver cancer	6.8e-06	4.76e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GOT1—liver cancer	6.75e-06	4.73e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GGT1—liver cancer	6.75e-06	4.73e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1B—liver cancer	6.75e-06	4.73e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARA—liver cancer	6.69e-06	4.68e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—liver cancer	6.69e-06	4.68e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—liver cancer	6.66e-06	4.67e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—liver cancer	6.66e-06	4.66e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—liver cancer	6.65e-06	4.66e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CB—liver cancer	6.64e-06	4.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—liver cancer	6.6e-06	4.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KDR—liver cancer	6.59e-06	4.61e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.55e-06	4.59e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK14—liver cancer	6.54e-06	4.58e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GLUL—liver cancer	6.51e-06	4.56e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CPT1B—liver cancer	6.51e-06	4.56e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—liver cancer	6.45e-06	4.52e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—liver cancer	6.43e-06	4.5e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—liver cancer	6.42e-06	4.5e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—JUN—liver cancer	6.42e-06	4.5e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ESR1—liver cancer	6.42e-06	4.5e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RAF1—liver cancer	6.42e-06	4.5e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	6.41e-06	4.49e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFB1—liver cancer	6.41e-06	4.49e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT3—liver cancer	6.39e-06	4.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CTNNB1—liver cancer	6.38e-06	4.47e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—liver cancer	6.37e-06	4.46e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—liver cancer	6.36e-06	4.45e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—F2—liver cancer	6.34e-06	4.44e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NR1H4—liver cancer	6.28e-06	4.4e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CB—liver cancer	6.27e-06	4.39e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MTOR—liver cancer	6.27e-06	4.39e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CG—liver cancer	6.24e-06	4.37e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1B—liver cancer	6.23e-06	4.36e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1A—liver cancer	6.23e-06	4.36e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTA3—liver cancer	6.17e-06	4.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—liver cancer	6.15e-06	4.31e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—liver cancer	6.08e-06	4.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK8—liver cancer	6.08e-06	4.26e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PSMD10—liver cancer	6.07e-06	4.25e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PSMA4—liver cancer	6.07e-06	4.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CG—liver cancer	6.07e-06	4.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APC—liver cancer	6.07e-06	4.25e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTP1—liver cancer	6.07e-06	4.25e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARG—liver cancer	6.02e-06	4.22e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—HMOX1—liver cancer	5.98e-06	4.19e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—liver cancer	5.94e-06	4.16e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—liver cancer	5.94e-06	4.16e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFB1—liver cancer	5.92e-06	4.15e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PIK3CA—liver cancer	5.91e-06	4.14e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GOT2—liver cancer	5.9e-06	4.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—liver cancer	5.9e-06	4.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CTNNB1—liver cancer	5.89e-06	4.12e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1B—liver cancer	5.88e-06	4.12e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—liver cancer	5.88e-06	4.12e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	5.79e-06	4.05e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—liver cancer	5.76e-06	4.04e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—liver cancer	5.75e-06	4.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1A—liver cancer	5.75e-06	4.03e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CG—liver cancer	5.73e-06	4.01e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BRAF—liver cancer	5.7e-06	4e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTA4—liver cancer	5.65e-06	3.95e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—liver cancer	5.61e-06	3.93e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—liver cancer	5.61e-06	3.93e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—JUN—liver cancer	5.6e-06	3.92e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTM1—liver cancer	5.58e-06	3.91e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT3—liver cancer	5.56e-06	3.89e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CTNNB1—liver cancer	5.55e-06	3.89e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP2E1—liver cancer	5.55e-06	3.89e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARG—liver cancer	5.53e-06	3.87e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTA2—liver cancer	5.5e-06	3.85e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CD—liver cancer	5.49e-06	3.84e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—liver cancer	5.49e-06	3.84e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—liver cancer	5.47e-06	3.83e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PIK3CA—liver cancer	5.45e-06	3.82e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—liver cancer	5.45e-06	3.81e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1A—liver cancer	5.43e-06	3.8e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALB—liver cancer	5.42e-06	3.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CD—liver cancer	5.33e-06	3.74e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTA1—liver cancer	5.31e-06	3.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK8—liver cancer	5.3e-06	3.71e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP1A1—liver cancer	5.29e-06	3.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SERPINE1—liver cancer	5.28e-06	3.7e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NAT2—liver cancer	5.25e-06	3.68e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	5.23e-06	3.67e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—liver cancer	5.23e-06	3.66e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYCS—liver cancer	5.19e-06	3.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—STAT3—liver cancer	5.13e-06	3.59e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GOT1—liver cancer	5.1e-06	3.57e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GGT1—liver cancer	5.1e-06	3.57e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—liver cancer	5.05e-06	3.53e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CA—liver cancer	5.04e-06	3.53e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CD—liver cancer	5.03e-06	3.53e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALDOB—liver cancer	5.03e-06	3.52e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALB—liver cancer	4.97e-06	3.48e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—MTHFR—liver cancer	4.93e-06	3.45e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—liver cancer	4.89e-06	3.43e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—liver cancer	4.88e-06	3.42e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STAT3—liver cancer	4.84e-06	3.39e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARA—liver cancer	4.83e-06	3.39e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—liver cancer	4.83e-06	3.38e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—liver cancer	4.83e-06	3.38e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CRABP1—liver cancer	4.8e-06	3.36e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CB—liver cancer	4.78e-06	3.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—liver cancer	4.77e-06	3.34e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—liver cancer	4.77e-06	3.34e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RAF1—liver cancer	4.76e-06	3.34e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFB1—liver cancer	4.76e-06	3.33e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—liver cancer	4.66e-06	3.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CB—liver cancer	4.65e-06	3.26e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTP1—liver cancer	4.58e-06	3.21e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—HMOX1—liver cancer	4.52e-06	3.16e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—liver cancer	4.5e-06	3.15e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFB1—liver cancer	4.49e-06	3.14e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—liver cancer	4.46e-06	3.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—liver cancer	4.46e-06	3.12e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—liver cancer	4.41e-06	3.09e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CB—liver cancer	4.39e-06	3.07e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CA—liver cancer	4.38e-06	3.07e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1B—liver cancer	4.36e-06	3.06e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—liver cancer	4.28e-06	3e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—liver cancer	4.27e-06	2.99e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTM1—liver cancer	4.21e-06	2.95e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HPGDS—liver cancer	4.2e-06	2.94e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—liver cancer	4.16e-06	2.92e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—liver cancer	4.16e-06	2.91e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—JUN—liver cancer	4.15e-06	2.91e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CG—liver cancer	4.14e-06	2.9e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CTNNB1—liver cancer	4.12e-06	2.89e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—liver cancer	4.12e-06	2.88e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—liver cancer	4.06e-06	2.84e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CA—liver cancer	4.05e-06	2.84e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—liver cancer	4.04e-06	2.83e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1A—liver cancer	4.03e-06	2.82e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARG—liver cancer	4e-06	2.8e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP1A1—liver cancer	3.99e-06	2.79e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK8—liver cancer	3.93e-06	2.75e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—liver cancer	3.88e-06	2.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CA—liver cancer	3.82e-06	2.68e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—liver cancer	3.74e-06	2.62e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PSMA4—liver cancer	3.74e-06	2.62e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PSMD10—liver cancer	3.74e-06	2.62e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—MTHFR—liver cancer	3.72e-06	2.6e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—liver cancer	3.69e-06	2.59e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARA—liver cancer	3.65e-06	2.56e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CD—liver cancer	3.64e-06	2.55e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GOT2—liver cancer	3.64e-06	2.55e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—liver cancer	3.63e-06	2.54e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT3—liver cancer	3.59e-06	2.52e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALB—liver cancer	3.59e-06	2.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—liver cancer	3.58e-06	2.51e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—liver cancer	3.58e-06	2.51e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—liver cancer	3.53e-06	2.48e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP2E1—liver cancer	3.42e-06	2.4e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—liver cancer	3.38e-06	2.37e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—liver cancer	3.34e-06	2.34e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFB1—liver cancer	3.33e-06	2.33e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—liver cancer	3.31e-06	2.32e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYCS—liver cancer	3.2e-06	2.24e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CB—liver cancer	3.17e-06	2.22e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GGT1—liver cancer	3.14e-06	2.2e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GOT1—liver cancer	3.14e-06	2.2e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CG—liver cancer	3.12e-06	2.19e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—liver cancer	3.12e-06	2.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—liver cancer	3.09e-06	2.16e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARG—liver cancer	3.02e-06	2.11e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CA—liver cancer	2.91e-06	2.04e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CA—liver cancer	2.83e-06	1.99e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTP1—liver cancer	2.82e-06	1.98e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HMOX1—liver cancer	2.78e-06	1.95e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CD—liver cancer	2.75e-06	1.92e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—liver cancer	2.74e-06	1.92e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALB—liver cancer	2.71e-06	1.9e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CA—liver cancer	2.68e-06	1.87e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—liver cancer	2.62e-06	1.84e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTM1—liver cancer	2.59e-06	1.82e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—liver cancer	2.51e-06	1.76e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP1A1—liver cancer	2.46e-06	1.72e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CB—liver cancer	2.39e-06	1.68e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—liver cancer	2.38e-06	1.67e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—liver cancer	2.32e-06	1.62e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—MTHFR—liver cancer	2.29e-06	1.6e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARA—liver cancer	2.25e-06	1.57e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—liver cancer	2.19e-06	1.53e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CA—liver cancer	1.93e-06	1.35e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CG—liver cancer	1.92e-06	1.35e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARG—liver cancer	1.86e-06	1.3e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CD—liver cancer	1.69e-06	1.19e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALB—liver cancer	1.67e-06	1.17e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—liver cancer	1.58e-06	1.11e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CB—liver cancer	1.47e-06	1.03e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CA—liver cancer	1.46e-06	1.02e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—liver cancer	1.19e-06	8.35e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CA—liver cancer	8.99e-07	6.3e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—liver cancer	7.34e-07	5.14e-06	CbGpPWpGaD
